Recent developments, however, suggest that strategies to treat pain are starting to match its complexity with a new ...

Drug developer Maze Therapeutics said on Monday it was targeting a valuation of up to $728.1 million in its New York initial ...

Perspective Therapeutics reports no dose-limiting toxicities or severe adverse events in Phase 1/2a trial of [212Pb]VMT-α-NET. Anti-tumor activity observed: 1 confirmed response (17 weeks), 2 ...

Patient-focused digital therapeutics that focus on specific diseases are enabling more patients to receive treatment at home and can now access more approvals and reimbursement pathways that offer ...

ISELIN, N.J., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United ...

A digital therapeutic (DTx) is defined as “health software intended to treat or alleviate a disease, disorder, condition, or injury by generating and delivering a medical intervention that has a ...

In the latest market close, Viking Therapeutics, Inc. (VKTX) reached $38.88, with a -1.09% movement compared to the previous day. The stock's change was less than the S&P 500's daily gain of 0.16%.

Despite the competitive threat posed by Eli Lilly’s acquisition of Scorpion Therapeutics’ STX-478, which has shown promising efficacy in several cancer types, Relay Therapeutics’ RLY-2608 ...

Jan 13 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday it plans to buy Scorpion Therapeutics' experimental cancer therapy for up to $2.5 billion in cash to expand its pipeline of ...

Just a month after announcing a $115 million series D financing to advance its lead assets, Maze Therapeutics is looking to boost its kidney disease candidates further by going public. The Bay ...

A new company is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug candidates and raising money from one of its original investors. The biotech ...

Treatments emerging from the digital therapeutics space were once greeted with optimism, due to the potential to aid patients’ health through technology, rather than pharmaceuticals. Ben ...